DE602004003577D1 - Schwimmende orale formulierungen mit kontrollierter freisetzung von betain - Google Patents
Schwimmende orale formulierungen mit kontrollierter freisetzung von betainInfo
- Publication number
- DE602004003577D1 DE602004003577D1 DE602004003577T DE602004003577T DE602004003577D1 DE 602004003577 D1 DE602004003577 D1 DE 602004003577D1 DE 602004003577 T DE602004003577 T DE 602004003577T DE 602004003577 T DE602004003577 T DE 602004003577T DE 602004003577 D1 DE602004003577 D1 DE 602004003577D1
- Authority
- DE
- Germany
- Prior art keywords
- betain
- controlled release
- oral formulations
- floating
- formulation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 239000000203 mixture Substances 0.000 title abstract 4
- KWIUHFFTVRNATP-UHFFFAOYSA-N glycine betaine Chemical compound C[N+](C)(C)CC([O-])=O KWIUHFFTVRNATP-UHFFFAOYSA-N 0.000 title abstract 3
- 238000013270 controlled release Methods 0.000 title 1
- 238000009472 formulation Methods 0.000 abstract 3
- KWIUHFFTVRNATP-UHFFFAOYSA-O N,N,N-trimethylglycinium Chemical compound C[N+](C)(C)CC(O)=O KWIUHFFTVRNATP-UHFFFAOYSA-O 0.000 abstract 2
- 229960003237 betaine Drugs 0.000 abstract 2
- 230000002496 gastric effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0065—Forms with gastric retention, e.g. floating on gastric juice, adhering to gastric mucosa, expanding to prevent passage through the pylorus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/205—Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
BE200300248 | 2003-04-17 | ||
BE200300248 | 2003-04-17 | ||
PCT/BE2004/000053 WO2004091601A1 (fr) | 2003-04-17 | 2004-04-18 | Formulations orales flottantes pour la liberation controlee de la betaine |
Publications (2)
Publication Number | Publication Date |
---|---|
DE602004003577D1 true DE602004003577D1 (de) | 2007-01-18 |
DE602004003577T2 DE602004003577T2 (de) | 2007-09-20 |
Family
ID=33163520
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE602004003577T Expired - Lifetime DE602004003577T2 (de) | 2003-04-17 | 2004-04-18 | Flottierende orale Formulierungen mit kontrollierter Freisetzung von Betain |
Country Status (7)
Country | Link |
---|---|
US (2) | US20060034918A1 (de) |
EP (1) | EP1615632B1 (de) |
AT (1) | ATE347358T1 (de) |
DE (1) | DE602004003577T2 (de) |
DK (1) | DK1615632T3 (de) |
ES (1) | ES2278314T3 (de) |
WO (1) | WO2004091601A1 (de) |
Families Citing this family (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7608640B2 (en) | 1999-03-02 | 2009-10-27 | Jallal Messadek | Glycine betaine and its use |
BE1013958A6 (fr) * | 2001-02-05 | 2003-01-14 | Messadek Jallal | Antagonistes glycoproteiques. |
BE1015608A6 (fr) | 2003-07-15 | 2005-06-07 | Messadek Jallal | Traitement des arterites. |
US20060160896A1 (en) * | 2002-02-04 | 2006-07-20 | Jallal Messadek | Therapeutic treatment |
DK1615632T3 (da) * | 2003-04-17 | 2007-04-10 | Jallal Messadek | Flydende orale formularer for kontrolleret udskillelse af betain |
BE1016128A6 (fr) * | 2004-07-22 | 2006-03-07 | Messadek Jallal | Combinaisons therapeutiques |
WO2006050581A2 (en) | 2004-11-10 | 2006-05-18 | Jallal Messadek | Betaine as agent against arthropod - or mosquito -borne diseases |
WO2006086856A1 (en) | 2005-02-15 | 2006-08-24 | Messadek, Jallal | Combination therapeutic compositions and method of use |
CA2650556A1 (en) | 2005-04-27 | 2006-11-02 | Jallal Messadek | Insulins combinations |
EP1933811A2 (de) * | 2005-09-30 | 2008-06-25 | Alza Corporation | Gebundene nanoteilchenförmige dosierformen einer wirkstoffformulierung mit kontrollierter freisetzung und verfahren |
WO2009020555A2 (en) | 2007-08-03 | 2009-02-12 | Glew Charles A | Compositions for compounding, extrusion and melt processing of foamable and cellular fluoropolymers |
WO2009065193A1 (en) * | 2007-11-21 | 2009-05-28 | Jallal Messadek | Treatment of aspirin resistance with betaine and/or betaine enriched molasses |
US8791045B2 (en) | 2011-11-09 | 2014-07-29 | Kimberly-Clark Worldwide, Inc. | Non-tacky wetness indicator composition for application on a polymeric substrate |
US9889222B2 (en) | 2011-11-09 | 2018-02-13 | Kimberly-Clark Worldwide, Inc. | Aqueous medium-sensitive coating compositions for triggered release of active ingredients and visual indication for wetness |
US9585826B2 (en) | 2012-11-07 | 2017-03-07 | Kimberly-Clark Worldwide, Inc. | Triggerable compositions for two-stage, controlled release of active chemistry |
US9119780B2 (en) | 2013-10-30 | 2015-09-01 | Kimberly-Clark Worldwide, Inc. | Triggerable compositions for two-stage, controlled release of proactive chemistry |
CN105796542A (zh) * | 2016-03-15 | 2016-07-27 | 四川九章生物科技有限公司 | 绿原酸在制备治疗以lag-3为靶点的疾病的药物中的用途 |
Family Cites Families (59)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE644568C (de) * | 1934-04-19 | 1937-05-07 | Bristol Aeroplane Co Ltd | Kopierfraesmaschine |
US3577534A (en) * | 1968-06-20 | 1971-05-04 | Canada Packers Ltd | Stable orally active heparinoid complexes |
GB1509979A (en) * | 1975-11-28 | 1978-05-10 | Fisons Ltd | Pharmaceutical compositions containing aspirin or indomethacin |
US4140755A (en) * | 1976-02-13 | 1979-02-20 | Hoffmann-La Roche Inc. | Sustained release tablet formulations |
US4605548A (en) * | 1983-05-31 | 1986-08-12 | Nitto Electric Industrial Co., Ltd. | Drug administration material |
GB8325627D0 (en) * | 1983-09-24 | 1983-10-26 | Scras | Therapeutic compositions |
PL149493B1 (en) * | 1985-04-12 | 1990-02-28 | Method of obtaining a tablet capable to buoy over surface of gastric juice | |
AU607172B2 (en) * | 1986-12-22 | 1991-02-28 | Cygnus, Inc. | Diffusion matrix for transdermal drug administration |
US4902718A (en) * | 1988-04-08 | 1990-02-20 | Bayless Robert K | Calcium homeostasis compositions and methods for controlling calcium metabolism |
US4968719A (en) * | 1989-04-03 | 1990-11-06 | Sigma Tau, Industrie Farmaceutiche Riunite Spa | Method for treating vascular disease |
EP0441119A3 (en) * | 1990-01-09 | 1992-10-14 | Richard D. Levere | The use of l-arginine in the treatment of hypertension and other vascular disorders |
US5405614A (en) * | 1992-04-08 | 1995-04-11 | International Medical Associates, Inc. | Electronic transdermal drug delivery system |
US5342621A (en) * | 1992-09-15 | 1994-08-30 | Advanced Cardiovascular Systems, Inc. | Antithrombogenic surface |
US5876780A (en) * | 1993-04-29 | 1999-03-02 | Cultor, Ltd. | Compositions for treating coccidiosis |
US5716941A (en) * | 1993-07-07 | 1998-02-10 | Biogenesys | Use of methyl donor compounds to treat neurological dysfunction associated with immune defects |
US5814599A (en) * | 1995-08-04 | 1998-09-29 | Massachusetts Insitiute Of Technology | Transdermal delivery of encapsulated drugs |
US6355166B1 (en) * | 1994-08-25 | 2002-03-12 | The University Of Iowa Research Foundation | Magnetically enhanced composite materials and methods for making and using the same |
US6056958A (en) * | 1994-12-09 | 2000-05-02 | Dupont Pharmaceuticals | Method of treatment of arterial and venous thromboembolic disorders |
US5961999A (en) * | 1995-06-08 | 1999-10-05 | Wella Aktiengesellschaft | Method of skin care using a skin care preparation containing a betaine ester and an α-hydroxy acid |
US6162926A (en) * | 1995-07-31 | 2000-12-19 | Sphere Biosystems, Inc. | Multi-substituted fullerenes and methods for their preparation and characterization |
US7045585B2 (en) * | 1995-11-30 | 2006-05-16 | Hamilton Civic Hospital Research Development Inc. | Methods of coating a device using anti-thrombin heparin |
AU2260397A (en) * | 1996-01-31 | 1997-08-22 | Trustees Of The University Of Pennsylvania, The | Remote control drug delivery device |
US5688499A (en) * | 1996-03-13 | 1997-11-18 | Queen's University At Kingston | Antagonism of endothelin actions |
US5880098A (en) * | 1996-04-12 | 1999-03-09 | Pharmacia & Upjohn Aktiebolag | Therapeutic treatment |
IL119029A0 (en) * | 1996-08-07 | 1996-11-14 | Yeda Res & Dev | Long-acting drugs and pharamaceutical compositions comprising them |
US6008221A (en) * | 1996-11-06 | 1999-12-28 | Bristol-Myers Squibb Company | Method for treating Alzheimer's disease with folic acid |
US6495579B1 (en) * | 1996-12-02 | 2002-12-17 | Angiotech Pharmaceuticals, Inc. | Method for treating multiple sclerosis |
US6235311B1 (en) * | 1998-03-18 | 2001-05-22 | Bristol-Myers Squibb Company | Pharmaceutical composition containing a combination of a statin and aspirin and method |
EP2338482A3 (de) * | 1998-04-14 | 2011-12-21 | The General Hospital Corporation | Verfahren zur Behandlung neuropsychischer Erkrankungen |
US6287765B1 (en) * | 1998-05-20 | 2001-09-11 | Molecular Machines, Inc. | Methods for detecting and identifying single molecules |
BE1013958A6 (fr) * | 2001-02-05 | 2003-01-14 | Messadek Jallal | Antagonistes glycoproteiques. |
US7608640B2 (en) * | 1999-03-02 | 2009-10-27 | Jallal Messadek | Glycine betaine and its use |
BE1012495A3 (fr) * | 1999-03-02 | 2000-11-07 | Messadek Jallal | La glycine-betaine pour son usage antithrombotique. |
AU2001257115B2 (en) * | 2000-04-20 | 2005-01-27 | Rtp Pharma Inc. | Improved water-insoluble drug particle process |
US6881420B2 (en) * | 2000-06-23 | 2005-04-19 | Teva Pharmaceutical Industries Ltd. | Compositions and dosage forms for gastric delivery of irinotecan and methods of treatment that use it to inhibit cancer cell proliferation |
US6476006B2 (en) * | 2000-06-23 | 2002-11-05 | Teva Pharmaceutical Industries, Ltd. | Composition and dosage form for delayed gastric release of alendronate and/or other bis-phosphonates |
CA2412490A1 (en) * | 2000-06-23 | 2002-01-03 | Moshe Fleshner-Barak | Rapidly expanding composition for gastric retention and controlled release of therapeutic agents, and dosage forms including the composition |
FR2811227A1 (fr) * | 2000-07-07 | 2002-01-11 | Philippe Maincent | Vecteurs particulaires destines a ameliorer l'absorption orale de principes actifs |
EP1351686A2 (de) * | 2000-11-20 | 2003-10-15 | Pharmacia Corporation | Substituierte polycyclische aryl- und heteroarylpyridine für die selektive hemmung der koagulationskaskade |
FI114538B (fi) * | 2001-01-12 | 2004-11-15 | Finnfeeds Finland Ltd | Glysiinibetaiinin käyttö verenpainetta alentavan tuotteen valmistukseen |
EP1408949B1 (de) * | 2001-02-05 | 2007-12-19 | Jallal Messadek | Antihaemorrhagische, betain-enthaltende zusammenseuzungen |
US20040072750A1 (en) * | 2001-05-03 | 2004-04-15 | David Phillips | Compounds and methods for the modulation of CD154 |
US6531171B2 (en) * | 2001-07-03 | 2003-03-11 | Nutricia Usa, Inc. | Food products containing betaine |
WO2003020260A1 (en) * | 2001-08-31 | 2003-03-13 | Metaproteomics, Llc | Arginine compositions for coordinate modification of multiple cardiovascular risk factors |
US20030170223A1 (en) * | 2002-02-01 | 2003-09-11 | Board Of Trustees Of Michigan State University | Pulmonary vasodilator surfactant compositions and method of use |
US20060160896A1 (en) * | 2002-02-04 | 2006-07-20 | Jallal Messadek | Therapeutic treatment |
US20030187074A1 (en) * | 2002-03-04 | 2003-10-02 | Javed Hussain | Oral compositions for treatment of diabetes |
EP2284535A1 (de) * | 2002-03-11 | 2011-02-16 | Momenta Pharmaceuticals, Inc. | Heparine mit niedrigem Molekulargewicht |
US7985422B2 (en) * | 2002-08-05 | 2011-07-26 | Torrent Pharmaceuticals Limited | Dosage form |
US20040067986A1 (en) * | 2002-10-04 | 2004-04-08 | Nathan Sassover | Neuro-degenerative inhibitor, neuro-endocrine modulator, and neuro-cerebral metabolism enhancer |
ES2364155T3 (es) * | 2002-11-25 | 2011-08-25 | Jallal Messadek | Composiciones de betaína y ácido acetilsalicílico. |
DK1615632T3 (da) * | 2003-04-17 | 2007-04-10 | Jallal Messadek | Flydende orale formularer for kontrolleret udskillelse af betain |
US7097968B2 (en) * | 2003-07-10 | 2006-08-29 | General Atomics | Methods and compositions for assaying homocysteine |
US20060128657A1 (en) * | 2003-08-04 | 2006-06-15 | Jallal Messadek | Selected betaines and their uses |
EP1755599A4 (de) * | 2004-04-23 | 2007-06-06 | Celgene Corp | Verfahren zur verwendung von thalidomid und dieses enthaltende zusammensetzungen zur behandlung und kontrolle von pulmonaler hypertonie |
BE1016128A6 (fr) * | 2004-07-22 | 2006-03-07 | Messadek Jallal | Combinaisons therapeutiques |
WO2006050581A2 (en) * | 2004-11-10 | 2006-05-18 | Jallal Messadek | Betaine as agent against arthropod - or mosquito -borne diseases |
WO2006086856A1 (en) * | 2005-02-15 | 2006-08-24 | Messadek, Jallal | Combination therapeutic compositions and method of use |
CA2650556A1 (en) * | 2005-04-27 | 2006-11-02 | Jallal Messadek | Insulins combinations |
-
2004
- 2004-04-18 DK DK04728127T patent/DK1615632T3/da active
- 2004-04-18 EP EP04728127A patent/EP1615632B1/de not_active Expired - Lifetime
- 2004-04-18 ES ES04728127T patent/ES2278314T3/es not_active Expired - Lifetime
- 2004-04-18 WO PCT/BE2004/000053 patent/WO2004091601A1/fr active IP Right Grant
- 2004-04-18 DE DE602004003577T patent/DE602004003577T2/de not_active Expired - Lifetime
- 2004-04-18 AT AT04728127T patent/ATE347358T1/de not_active IP Right Cessation
-
2005
- 2005-10-17 US US11/251,737 patent/US20060034918A1/en not_active Abandoned
-
2010
- 2010-02-11 US US12/704,294 patent/US20100221330A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
ES2278314T3 (es) | 2007-08-01 |
US20060034918A1 (en) | 2006-02-16 |
DE602004003577T2 (de) | 2007-09-20 |
EP1615632B1 (de) | 2006-12-06 |
ATE347358T1 (de) | 2006-12-15 |
EP1615632A1 (de) | 2006-01-18 |
DK1615632T3 (da) | 2007-04-10 |
US20100221330A1 (en) | 2010-09-02 |
WO2004091601A1 (fr) | 2004-10-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ATE347358T1 (de) | Schwimmende orale formulierungen mit kontrollierter freisetzung von betain | |
BG66093B1 (bg) | Състави с контролирано освобождаване, съдържащи нимесулид | |
DE122008000001I1 (de) | Orale Dosiszusammensetzungen mit verlängerter Freigabe | |
ITMI20011337A0 (it) | Composizioni farmaceutiche orali a rilascio modificato del principio attivo | |
NO20043998L (no) | Oral administreringsform for tungtloselige basiske aktive virkestoffer | |
DE50212546D1 (de) | Orale darreichungsformen für propiverin oder seinen pharmazeutisch annehmbaren salzen mit verlängerter wirkstofffreisetzung | |
DE60316323D1 (de) | Feste pharmazeutische formulierungen mit telmisartan | |
CA3094580A1 (en) | Oral formulations of cytidine analogs and methods of use thereof | |
DE60131703D1 (de) | Orale feste pharmazeutische Zusammensetzungen zur pH-abhängig mehrphasigen Freisetzung | |
AR037490A1 (es) | Composiciones farmaceuticas solidas, proceso para su preparacion, kit para el tratamiento de la obesidad y uso de dichas composiciones en la elaboracion de medicamentos | |
IL183357A0 (en) | Oral medicament for the modified release of at least one active principle, in multimicrocapsule form | |
RS54398B1 (en) | THE USE OF FLIBANSERINE FOR THE TREATMENT OF SEXUAL DESIRE DISORDERS IN POSTMENOPAUSE | |
HN2003000183A (es) | Difenilazetidinonas sustituidas en anillo procedimiento para su preparacion, medicamentos que comprenden estos compuestos y su uso. | |
ATE260650T1 (de) | Orale darreichungsformen zur verabreichung einer fixen kombination von tramadol und diclofenac | |
ATE541562T1 (de) | Ibuprofen-suspension | |
ATE499939T1 (de) | Neue pharmazeutische zusammenstezungen, flibanserin polymorph a enthaltend | |
RS50768B (sr) | Režim doziranja i farmaceutska formulacija za urgentnu zaštitu | |
ATE505203T1 (de) | Pharmazeutische kombination aus aliskiren und valsartan | |
AR034517A1 (es) | Formulacion farmaceutica | |
RU2007122391A (ru) | S-миртазапин для лечения приливов | |
BR0112847A (pt) | Uso de uma forma de dosagem sólida | |
CO5560554A2 (es) | Composicion farmaceutica que comprende lumiracoxib | |
ITMI20011338A0 (it) | Composizioni farmaceutiche orali a rilascio immediato del principio attivo | |
NO20051261L (no) | Morfin-6-glukuronidsalt | |
MXPA05008403A (es) | Uso de acido comestible en formas de dosis solidas farmaceuticas de rapida dispersion. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
8364 | No opposition during term of opposition |